The National Comprehensive Cancer Network (NCCN) has published updated data on generic cancer medication shortages in the US, ...
Gavin Wright, MBBS, explains what the phase 3 VISUALIZE 2 trial aims to confirm about abenacianine's surgical benefit for patients with lung cancer. This is part 2 of a 2-part interview. Watch part 1 ...
David DiBardino, MD, explains why intratumoral therapy emerged in lung cancer and the open questions in standardizing how ...
Thoracotomy and intercostal minimally invasive approaches can precipitate post-thoracotomy pain syndrome via intercostal ...
The FDA has granted final approval to a laurylsulfate salt formulation of cabozantinib (Omcazio), converting the product’s ...
Ku explains how many bispecific antibodies can act as molecular bridges, binding a tumor-associated antigen such as ...
Burnout remains a significant concern among oncologists, with approximately 60% of oncologists reporting burnout, according ...
Pollack, MD, and participants discussed how the practical burden of toxicity monitoring is increasingly steering the choice ...
The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed ...
The FDA has extended the Prescription Drug User Fee Act (PDUFA) action date by 3 months to March 3, 2027, for the new drug ...
Jonathan Villena-Vargas, MD, explains how a subcostal robotic approach avoids intercostal nerve damage, cutting ...
Learn why "life years saved" better captures progress in blood cancer than 5-year survival rates, with insights from Dr. E. Anders Kolb of Blood Cancer United.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results